Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study Abstract #1503

Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.
Aim(s): To assess the impact of prior SSA on PFS in the RADIANT-4 study.
Materials and methods: Pts were randomized (2:1) to receive EVE 10 mg/day or PBO. This analysis reports baseline characteristics, PFS, and safety by prior SSA use.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Roberto Buzzoni

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience
Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: everolimus SSA
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
#1502 Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.
Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Rodney Pommier
#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial
Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Matthew H Kulke